Table 2.
Effects of various long-term dosing regimens of Hiltonol® on survival of BALB/c mice with a lethal SARS-CoV infection.
| Treatment | Dosing regimen (day prior to virus exposure) | Survivors/total | Mean day of death ± SD |
|---|---|---|---|
| PSS | 21 | 0/10 | 4.4 ± 1.8 |
| Hiltonol® (2.5 mg/kg/day) | 21 | 10/10*** | >21*** |
| Hiltonol® (0.75 mg/kg/day) | 21 | 1/10 | 5.0 ± 0.9 |
| PSS | 14 | 0/10 | 3.8 ± 0.6 |
| Hiltonol® (2.5 mg/kg/day) | 14 | 9/10*** | 5.0 ± 0.0 |
| Hiltonol® (0.75 mg/kg/day) | 14 | 9/10*** | 4.0 ± 0.0 |
| PSS | 7 | 0/10 | 3.7 ± 0.5 |
| Hiltonol® (2.5 mg/kg/day) | 7 | 10/10*** | >21*** |
| Hiltonol® (0.75 mg/kg/day) | 7 | 10/10*** | >21*** |
| Ampligen® (10 mg/kg/day) | bid x 2, beg −4 h | 5/10* | 5.8 ± 2.4 |
*p < 0.05, ***p < 0.001 compared to PSS control.